NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price, Price Target & More

$157.75 -1.80 (-1.13 %)

(As of 04/20/2018 02:12 PM ET)

Previous Close$159.55

Today's Range$157.58 - $160.78

52-Week Range$113.66 - $178.25

Volume802,459 shs

Average Volume1.72 million shs

Market Capitalization$41.64 billion

P/E Ratio197.06

Dividend YieldN/A

Beta1.49

About Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:VRTX

CUSIP92532F10

Webwww.vrtx.com

Phone617-341-6100

Debt

Debt-to-Equity Ratio0.01%

Current Ratio3.28%

Quick Ratio3.14%

Price-To-Earnings

Trailing P/E Ratio197.06

Forward P/E RatioN/A

P/E Growth2.21

Sales & Book Value

Annual Sales$2.49 billion

Price / Sales16.16

Cash Flow$1.0126 per share

Price / Cash155.78

Book Value$8.08 per share

Price / Book19.52

Profitability

EPS (Most Recent Fiscal Year)$0.80

Net Income$263.48 million

Net Margins10.59%

Return on Equity11.02%

Return on Assets6.28%

Miscellaneous

Employees2,300

Outstanding Shares254,880,000

How to Become a New Pot Stock Millionaire

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals announced that its Board of Directors has initiated a share buyback program on Thursday, February 1st 2018, which permits the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company's board of directors believes its stock is undervalued.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals (NASDAQ:VRTX) announced its quarterly earnings results on Wednesday, January, 31st. The pharmaceutical company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.53 by $0.08. The pharmaceutical company had revenue of $651.63 million for the quarter, compared to the consensus estimate of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The company's quarterly revenue was up 42.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 EPS. View Vertex Pharmaceuticals' Earnings History.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Vertex Pharmaceuticals.

What price target have analysts set for VRTX?

27 brokerages have issued twelve-month price objectives for Vertex Pharmaceuticals' stock. Their predictions range from $98.00 to $211.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $184.3846 in the next year. View Analyst Ratings for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:

1. According to Zacks Investment Research, "Vertex’ efforts to get its two CF drugs — Kalydeco & Orkambi — approved for additional indications are encouraging. In 2017, positive data read-outs and regulatory approvals have increased the eligible patient population for Kalydeco & Orkambi, which is driving sales growth. Vertex’s CF pipeline is also quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth, as they have the potential to treat up to 90% of CF patients. The FDA approval of the third CF medicine, Symdeko, in February was encouraging. The stock has outperformed the industry this year so far. However, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Estimate movement has been mixed ahead of Q1 earnings release. Vertex has a positive record of earnings surprises in the recent quarters." (4/20/2018)
2. HC Wainwright analysts commented, "Halts Triple Combination Trials in France as a Protest in Pricing Negotiations What’s new? We have recently learned via a twitter comment and associated article (http://bit.ly/2Bp7vL7) that Vertex has decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis (CF) in France. During the Vertex 4Q earnings call, management identified the two second-generation correctors that would be added to the combination of tezacaftor/ivacaftor to formulate the triple combination. It appears that these trials will continue in the US and other parts of Europe but will now be excluding France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. As mentioned in the article, this is a disappointment to the French CF patients that have been consistent participants in numerous trials to date and were eagerly awaiting more rapid access to what could be the most effective modulator treatment yet for CF." (2/13/2018)
3. Maxim Group analysts commented, "On January 8 at the JP Morgan Conference, Vertex reiterated 2017 Cystic Fibrosis (CF) revenue of $2.1B – $2.15B, an increase of 23% from YE-2016 and in-line with our model. As of the last update following 3Q17, Vertex guided YE-2017 Kalydeco revenue of $810M-$830M, Orkambi revenue of $1.29B- $1.32B and non-GAAP operating expenses of $1.33B-$1.36B, each in-line with our model. Street consensus estimates for 4Q17 for Kalydeco revenue is $230.6M vs. our estimate of $236.7M, Orkambi revenue of $359.9M vs. our estimate of $378.7M, non-GAAP opex of $356M vs. our estimate of $352.4M and non-GAAP EPS of $0.53 vs. our estimate of $0.63." (1/31/2018)

Who are some of Vertex Pharmaceuticals' key competitors?

Some companies that are related to Vertex Pharmaceuticals include Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Nektar Therapeutics (NKTR), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Genmab As (GNMSF), Perrigo (PRGO) and Alnylam Pharmaceuticals (ALNY).

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the folowing people:

Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 62)
Mr. Ian F. Smith, Exec. VP & COO (Age 52)
Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 53)
Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 43)
Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 50)

Has Vertex Pharmaceuticals been receiving favorable news coverage?

News stories about VRTX stock have been trending somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also assigned media headlines about the pharmaceutical company an impact score of 45.41 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $157.75.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $41.64 billion and generates $2.49 billion in revenue each year. The pharmaceutical company earns $263.48 million in net income (profit) each year or $0.80 on an earnings per share basis. Vertex Pharmaceuticals employs 2,300 workers across the globe.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]

MarketBeat Community Rating for Vertex Pharmaceuticals (VRTX)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		1,064 (Vote Outperform)
Underperform Votes:		592 (Vote Underperform)
Total Votes:		1,656

MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

27 Wall Street analysts have issued ratings and price targets for Vertex Pharmaceuticals in the last 12 months. Their average twelve-month price target is $184.3846, suggesting that the stock has a possible upside of 16.88%. The high price target for VRTX is $211.00 and the low price target for VRTX is $98.00. There are currently 2 hold ratings and 25 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.93	2.93	2.93	2.85
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 25 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 25 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 25 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 23 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$184.3846	$184.3846	$175.68	$166.4615
Price Target Upside:	16.88% upside	8.42% upside	12.64% upside	7.36% upside

Vertex Pharmaceuticals (NASDAQ:VRTX) Consensus Price Target History

Price Target History for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/5/2018	Maxim Group	Boost Price Target	Buy -> Buy	$195.00 -> $200.00	Medium
2/23/2018	Argus	Set Price Target	Buy -> Buy	$194.00	High
2/13/2018	JMP Securities	Reiterated Rating	Market Outperform -> Outperform	$200.00 -> $211.00	Low
2/13/2018	Credit Suisse Group	Boost Price Target	Outperform -> Outperform	$195.00 -> $196.00	Low
2/13/2018	HC Wainwright	Reiterated Rating	Hold	$103.00	Low
2/2/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$198.00 -> $200.00	Medium
2/1/2018	Bank of America	Boost Price Target	Buy -> Buy	$180.00 -> $197.00	High
2/1/2018	Citigroup	Reiterated Rating	Buy		High
2/1/2018	BMO Capital Markets	Boost Price Target	Outperform -> Buy	$184.00 -> $191.00	High
2/1/2018	Leerink Swann	Reiterated Rating	Outperform	$175.00 -> $190.00	High
2/1/2018	Royal Bank of Canada	Boost Price Target	Outperform	$200.00	High
2/1/2018	Jefferies Group	Reiterated Rating	Buy	$195.00	High
2/1/2018	Barclays	Boost Price Target	Overweight -> Overweight	$180.00 -> $200.00	High
1/9/2018	JPMorgan Chase	Reiterated Rating	Buy		Low
1/4/2018	Oppenheimer	Boost Price Target	Outperform	$175.00 -> $190.00	Low
12/12/2017	Deutsche Bank	Initiated Coverage	Buy	$175.00	High
12/11/2017	Cowen	Reiterated Rating	Buy	$200.00	Low
10/27/2017	Needham & Company LLC	Reiterated Rating	Buy	$195.00	N/A
10/27/2017	Robert W. Baird	Reiterated Rating	Buy		N/A
10/26/2017	Piper Jaffray	Reiterated Rating	Overweight	$205.00	N/A
9/29/2017	DA Davidson	Initiated Coverage	Buy	$200.00	Low
9/29/2017	BTIG Research	Initiated Coverage	Buy -> Buy	$200.00	Medium
7/19/2017	UBS	Downgrade	Buy -> Neutral	$135.00 -> $174.00	High
7/19/2017	Raymond James	Upgrade	Market Perform -> Outperform	$181.00	High
7/19/2017	Janney Montgomery Scott	Upgrade	Neutral -> Buy	$98.00	High
7/18/2017	Stifel Nicolaus	Boost Price Target	Buy -> Buy	$130.00 -> $154.00	High
6/2/2017	CIBC	Upgrade	Market Perform -> Outperform		Low
11/1/2016	William Blair	Downgrade	Outperform -> Market Perform	$105.00 -> $81.00	N/A
4/28/2016	Goldman Sachs	Downgrade	Buy -> Neutral	$109.00 -> $88.00	N/A

(Data available from 4/20/2016 forward)

Vertex Pharmaceuticals (NASDAQ:VRTX) Earnings History and Estimates Chart

Earnings by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) Earnings Estimates

2018 EPS Consensus Estimate: $1.69

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.30	$0.34	$0.32
Q2 2018	3	$0.26	$0.36	$0.33
Q3 2018	2	$0.44	$0.47	$0.46
Q4 2018	2	$0.57	$0.61	$0.59

Vertex Pharmaceuticals (NASDAQ VRTX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/26/2018		$0.60					N/A
1/31/2018	Q4 2017	$0.53	$0.61	$592.49 million	$651.63 million	View	N/A
10/25/2017	Q3 2017	$0.04	$0.53	$522.07 million	$578.20 million	View	N/A
7/26/2017	Q2 2017	$0.06	$0.39	$489.95 million	$544.10 million	View	N/A
4/27/2017	Q1 2017	$0.04	$0.13	$692.64 million	$714.72 million	View	N/A
1/25/2017	Q4 2016	$0.29	$0.35	$453.40 million	$458.71 million	View	N/A
10/25/2016	Q316	$0.18	$0.16	$423.53 million	$413.78 million	View	Listen
7/27/2016	Q216	$0.21	$0.24	$428.08 million	$431.61 million	View	Listen
4/27/2016	Q116	$0.29	$0.09	$439.94 million	$398.10 million	View	Listen
1/27/2016	Q4	$0.17	$0.17	$406.30 million	$417.94 million	View	Listen
10/28/2015	Q315	($0.60)	($0.13)	$245.84 million	$309.82 million	View	Listen
7/29/2015	Q215	($0.58)	($0.54)	$149.49 million	$166.00 million	View	Listen
4/29/2015	Q115	($0.75)	($0.62)	$142.38 million	$138.51 million	View	Listen
1/28/2015	Q414	($0.65)	($0.55)	$137.50 million	$144.56 million	View	Listen
10/28/2014	Q314	($0.62)	($0.37)	$146.20 million	$179.00 million	View	N/A
7/29/2014	Q214	($0.71)	($0.61)	$131.85 million	$138.42 million	View	Listen
5/1/2014	Q114	($0.68)	($0.65)	$134.46 million	$118.50 million	View	N/A
1/29/2014	Q413	($0.49)	($0.56)	$221.08 million	$351.20 million	View	Listen
10/29/2013	Q413	($0.33)	($0.32)	$278.80 million	$222.00 million	View	N/A
7/29/2013	Q2 2013	($0.18)	($0.26)	$308.02 million	$310.80 million	View	N/A
4/30/2013	Q1 2013	($0.06)	$0.03	$307.85 million	$328.40 million	View	N/A
1/29/2013	Q4 2012	($0.07)	($0.35)	$318.53 million	$334.00 million	View	N/A
11/1/2012	Q312	$0.34	$0.13	$377.14 million	$336.00 million	View	N/A
7/30/2012		$0.68	$0.46			View	N/A
4/26/2012		$0.57	$0.43			View	N/A
2/2/2012		$0.76	$0.74			View	N/A
10/27/2011		$0.17	$0.70			View	N/A
7/28/2011		($1.00)	($0.67)			View	N/A
5/3/2011		($1.09)	($0.91)			View	N/A
2/3/2011		($0.93)	($0.74)			View	N/A
10/25/2010	Q3 2010	($0.91)	($0.99)			View	N/A
7/28/2010	Q2 2010	($0.83)	($0.83)			View	N/A
4/21/2010	Q1 2010	($0.78)	($0.80)			View	N/A
2/4/2010	Q4 2009	($0.85)	($0.75)			View	N/A
10/26/2009	Q3 2009	($0.80)	($0.83)			View	N/A
8/5/2009	Q2 2009	($0.80)	($0.92)			View	N/A
4/16/2009	Q1 2009	($0.84)	($0.97)			View	N/A
2/9/2009	Q4 2008	($0.92)	($0.95)			View	N/A
10/27/2008	Q3 2008	($0.91)	($0.93)			View	N/A
7/31/2008	Q2 2008	($0.62)	($0.65)			View	N/A
4/21/2008	Q1 2008	($0.63)	($0.72)			View	N/A
2/11/2008	Q4 2007	($0.69)	($0.66)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Vertex Pharmaceuticals (NASDAQ:VRTX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/29/2013	quarterly	$0.40			2/20/2013	3/13/2013

(Data available from 1/1/2013 forward)

Vertex Pharmaceuticals (NASDAQ VRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 94.17%

Insider Trading History for Vertex Pharmaceuticals (NASDAQ:VRTX)

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ VRTX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/18/2018	Paul M Silva	SVP	Sell	859	$166.05	$142,636.95	16,946
4/16/2018	Stuart A Arbuckle	EVP	Sell	2,125	$163.01	$346,396.25	48,877
4/2/2018	Paul M Silva	SVP	Sell	3,438	$161.21	$554,239.98	16,225
3/9/2018	Amit Sachdev	EVP	Sell	13,750	$175.00	$2,406,250.00	60,412
3/2/2018	Margaret G Mcglynn	Director	Sell	10,000	$170.00	$1,700,000.00	16,312
2/26/2018	Stuart A Arbuckle	EVP	Sell	6,459	$169.00	$1,091,571.00	53,211
2/20/2018	Paul M Silva	SVP	Sell	3,437	$158.49	$544,730.13	19,525
2/12/2018	Jeffrey Chodakewitz	CMO	Sell	5,122	$150.82	$772,500.04	73,485
2/12/2018	Jeffrey M Leiden	CEO	Sell	23,905	$150.83	$3,605,591.15	208,463
2/12/2018	Michael Parini	EVP	Sell	12,136	$153.41	$1,861,783.76	74,652
2/12/2018	Paul M Silva	SVP	Sell	4,213	$153.41	$646,316.33
2/5/2018	Amit Sachdev	EVP	Sell	4,520	$163.01	$736,805.20	46,202
2/5/2018	Jeffrey Chodakewitz	CMO	Sell	3,594	$161.46	$580,287.24	56,118
2/5/2018	Paul M Silva	SVP	Sell	2,098	$163.08	$342,141.84	17,923
2/2/2018	Jeffrey Chodakewitz	CMO	Sell	3,696	$166.79	$616,455.84	52,524
2/2/2018	Paul M Silva	SVP	Sell	9,883	$173.50	$1,714,700.50	25,228
2/2/2018	Stuart A Arbuckle	EVP	Sell	2,156	$169.42	$365,269.52	44,108
1/29/2018	Amit Sachdev	EVP	Sell	15,085	$170.00	$2,564,450.00	54,248
1/24/2018	Stuart A Arbuckle	EVP	Sell	8,969	$169.00	$1,515,761.00	46,262
1/23/2018	Margaret G Mcglynn	Director	Sell	20,000	$162.50	$3,250,000.00	16,217
1/23/2018	Paul M Silva	SVP	Sell	5,435	$164.03	$891,503.05	19,061
1/22/2018	Amit Sachdev	EVP	Sell	46,172	$158.65	$7,325,187.80	57,835
1/19/2018	Amit Sachdev	EVP	Sell	32,422	$158.08	$5,125,269.76	57,835
1/16/2018	Jeffrey Chodakewitz	CMO	Sell	1,719	$157.28	$270,364.32	56,143
1/16/2018	Jeffrey M Leiden	CEO	Sell	99,563	$156.99	$15,630,395.37	176,747
1/16/2018	Stuart A Arbuckle	EVP	Sell	2,125	$158.28	$336,345.00	44,077
1/11/2018	Stuart A Arbuckle	EVP	Sell	4,250	$159.00	$675,750.00	46,202
1/5/2018	Sangeeta N Bhatia	Director	Sell	10,753	$156.00	$1,677,468.00	14,706
1/2/2018	Jeffrey Chodakewitz	CMO	Sell	3,438	$151.80	$521,888.40	57,862
1/2/2018	Thomas Graney	CFO	Sell	777	$149.95	$116,511.15
12/27/2017	Paul M Silva	SVP	Sell	1,289	$152.31	$196,327.59	17,923
12/11/2017	Jeffrey M Leiden	CEO	Sell	125,000	$141.35	$17,668,750.00	237,407
11/15/2017	Stuart A Arbuckle	EVP	Sell	221	$147.29	$32,551.09
11/6/2017	Ian F Smith	COO	Sell	6,405	$150.00	$960,750.00
11/6/2017	Stuart A Arbuckle	EVP	Sell	4,250	$148.17	$629,722.50	46,202
11/3/2017	Ian F Smith	COO	Sell	2,155	$150.00	$323,250.00	43,043
11/3/2017	Jeffrey Chodakewitz	CMO	Sell	5,390	$144.71	$779,986.90	56,220
11/3/2017	Michael Parini	EVP	Sell	2,330	$149.50	$348,335.00	31,139
11/3/2017	Sangeeta N Bhatia	Director	Sell	7,073	$143.05	$1,011,792.65	11,026
10/31/2017	Amit Sachdev	EVP	Sell	40,000	$145.05	$5,802,000.00	89,810
10/31/2017	Ian F Smith	COO	Sell	75,000	$145.06	$10,879,500.00	114,188
10/31/2017	Jeffrey Chodakewitz	CMO	Sell	60,000	$145.05	$8,703,000.00	113,024
10/27/2017	Stuart A Arbuckle	EVP	Sell	6,290	$143.97	$905,571.30	116,952
10/16/2017	Ian F Smith	COO	Sell	2,125	$155.61	$330,671.25	118,013
10/16/2017	Jeffrey Chodakewitz	CMO	Sell	1,718	$155.19	$266,616.42	116,142
10/12/2017	Michael Parini	EVP	Sell	2,125	$152.93	$324,976.25
10/2/2017	Jeffrey Chodakewitz	CMO	Sell	3,437	$151.64	$521,186.68
8/31/2017	David Altshuler	EVP	Sell	1,796	$160.00	$287,360.00	107,807
8/7/2017	Ian F Smith	CFO	Sell	4,250	$155.39	$660,407.50	120,138
8/7/2017	Paul M Silva	SVP	Sell	1,289	$152.88	$197,062.32	17,923
8/3/2017	Jeffrey Chodakewitz	CMO	Sell	5,390	$154.17	$830,976.30	116,220
8/3/2017	Michael Parini	EVP	Sell	2,330	$155.72	$362,827.60	31,139
8/2/2017	Ian F Smith	CFO	Sell	2,155	$154.17	$332,236.35	118,043
8/2/2017	Jeffrey Chodakewitz	CMO	Sell	1,796	$154.13	$276,817.48	116,220
8/2/2017	Paul M Silva	SVP	Sell	1,289	$151.80	$195,670.20	17,923
7/31/2017	Jeffrey M Leiden	CEO	Sell	11,063	$152.81	$1,690,537.03	268,455
7/31/2017	Paul M Silva	SVP	Sell	860	$152.99	$131,571.40	17,494
7/31/2017	Stuart A Arbuckle	EVP	Sell	2,125	$152.99	$325,103.75	123,242
7/21/2017	Amit Sachdev	EVP	Sell	28,625	$160.93	$4,606,621.25	119,335
7/21/2017	Ian F Smith	CFO	Sell	133,750	$160.98	$21,531,075.00	151,738
7/21/2017	Jeffrey Chodakewitz	CMO	Sell	46,733	$160.96	$7,522,143.68	128,814
7/21/2017	Jeffrey M Leiden	CEO	Sell	216,624	$160.96	$34,867,799.04	400,266
7/21/2017	Paul M Silva	SVP	Sell	43,443	$161.07	$6,997,364.01	26,516
7/19/2017	Michael Parini	EVP	Sell	10,829	$161.00	$1,743,469.00	37,309
7/17/2017	Jeffrey Chodakewitz	CMO	Sell	573	$129.85	$74,404.05	123,084
7/3/2017	Jeffrey Chodakewitz	CMO	Sell	3,438	$127.80	$439,376.40	125,949
6/21/2017	Jeffrey Chodakewitz	CMO	Sell	5,157	$132.87	$685,210.59	127,668
6/21/2017	Paul M Silva	SVP	Sell	2,577	$133.36	$343,668.72	22,648
6/5/2017	David Altshuler	EVP	Sell	7,500	$130.00	$975,000.00	113,511
6/2/2017	Jeffrey M Leiden	CEO	Sell	147,101	$129.50	$19,049,579.50	312,142
6/2/2017	Sangeeta N Bhatia	Director	Sell	1,176	$128.44	$151,045.44	5,129
6/2/2017	Stuart A Arbuckle	EVP	Sell	70,969	$128.06	$9,088,290.14	145,061
5/2/2017	Jeffrey Chodakewitz	CMO	Sell	8,979	$121.05	$1,086,907.95	131,490
4/28/2017	Jeffrey M Leiden	CEO	Sell	157,200	$119.50	$18,785,400.00	395,152
4/5/2017	Jeffrey Chodakewitz	CMO	Sell	8,021	$114.00	$914,394.00	130,532
4/3/2017	Jeffrey Chodakewitz	CMO	Sell	2,291	$108.85	$249,375.35	124,802
3/29/2017	Amit Sachdev	EVP	Sell	80,500	$107.63	$8,664,215.00	105,054
3/29/2017	Jeffrey Chodakewitz	CMO	Sell	13,750	$106.65	$1,466,437.50	136,261
3/29/2017	Paul M Silva	SVP	Sell	1,688	$106.30	$179,434.40	21,759
1/11/2017	Joshua S Boger	Director	Sell	8,000	$82.48	$659,840.00	276,225
1/4/2017	Joshua S Boger	Director	Sell	6,500	$77.13	$501,345.00	274,725
12/29/2016	Joshua S Boger	Director	Sell	6,500	$74.33	$483,145.00	274,725
12/21/2016	Joshua S Boger	Director	Sell	6,500	$74.16	$482,040.00	274,725
12/14/2016	Joshua S Boger	Director	Sell	6,500	$77.52	$503,880.00	274,725
11/30/2016	Joshua S Boger	Director	Sell	6,500	$83.48	$542,620.00	274,725
11/23/2016	Joshua S Boger	Director	Sell	6,500	$86.47	$562,055.00	274,725
11/16/2016	Joshua S Boger	Director	Sell	6,500	$91.55	$595,075.00	274,725
11/10/2016	Paul M Silva	SVP	Sell	5,062	$90.98	$460,540.76	17,125
11/9/2016	Joshua S Boger	Director	Sell	6,500	$90.98	$591,370.00	274,725
11/9/2016	Stuart A Arbuckle	EVP	Sell	1,208	$90.00	$108,720.00	113,358
11/2/2016	Joshua S Boger	Director	Sell	6,500	$77.75	$505,375.00	274,725
10/26/2016	Joshua S Boger	Director	Sell	6,500	$79.26	$515,190.00	274,725
10/19/2016	Joshua S Boger	Director	Sell	6,500	$81.84	$531,960.00	274,725
10/12/2016	Joshua S Boger	Director	Sell	6,500	$81.14	$527,410.00	274,725
10/5/2016	Joshua S Boger	Director	Sell	6,500	$87.44	$568,360.00	274,725
10/3/2016	Stuart A Arbuckle	EVP	Sell	1,208	$86.46	$104,443.68	114,566
9/28/2016	Joshua S Boger	Director	Sell	6,500	$88.15	$572,975.00	274,725
9/21/2016	Joshua S Boger	Director	Sell	6,500	$90.82	$590,330.00	274,725
9/14/2016	Joshua S Boger	Director	Sell	6,500	$92.37	$600,405.00	274,725
9/7/2016	Joshua S Boger	Director	Sell	6,500	$95.66	$621,790.00	274,725
8/31/2016	Joshua S Boger	Director	Sell	6,500	$94.62	$615,030.00	274,725
8/24/2016	Joshua S Boger	Director	Sell	7,500	$100.46	$753,450.00	274,725
8/22/2016	Joshua S Boger	Director	Sell	1,100	$100.79	$110,869.00	268,225
8/17/2016	Joshua S Boger	Director	Sell	6,900	$99.63	$687,447.00	274,725
8/11/2016	Joshua S Boger	Director	Sell	900	$100.19	$90,171.00	268,225
8/10/2016	Joshua S Boger	Director	Sell	7,100	$100.24	$711,704.00	274,725
8/3/2016	Joshua S Boger	Director	Sell	47,000	$100.66	$4,731,020.00	274,725
7/27/2016	Joshua S Boger	Director	Sell	6,500	$95.93	$623,545.00	274,725
7/20/2016	Joshua S Boger	Director	Sell	6,500	$90.33	$587,145.00	274,725
7/13/2016	Joshua S Boger	Director	Sell	6,500	$88.81	$577,265.00	274,725
7/6/2016	Joshua S Boger	Director	Sell	5,140	$88.99	$457,408.60	273,365
6/29/2016	Joshua S Boger	Director	Sell	5,130	$84.82	$435,126.60	273,355
6/22/2016	Joshua S Boger	Director	Sell	5,130	$86.61	$444,309.30	273,355
6/15/2016	Joshua S Boger	Director	Sell	5,130	$91.18	$467,753.40	273,355
6/8/2016	Joshua S Boger	Director	Sell	5,130	$94.95	$487,093.50	273,355
6/1/2016	Joshua S Boger	Director	Sell	5,130	$93.65	$480,424.50	268,225
5/25/2016	Joshua S Boger	Director	Sell	5,130	$89.09	$457,031.70	270,414
5/18/2016	Joshua S Boger	Director	Sell	5,130	$81.18	$416,453.40	270,414
5/16/2016	Amit Sachdev	EVP	Sell	117	$81.67	$9,555.39	86,096
5/16/2016	Ian F Smith	CFO	Sell	202	$82.06	$16,576.12	112,999
5/11/2016	Joshua S Boger	Director	Sell	5,130	$86.50	$443,745.00	270,414
5/9/2016	Paul M Silva	SVP	Sell	3,000	$87.63	$262,890.00	15,950
5/4/2016	Joshua S Boger	Director	Sell	5,130	$81.02	$415,632.60	270,414
4/27/2016	Joshua S Boger	Director	Sell	5,130	$83.67	$429,227.10	270,414
4/20/2016	Joshua S Boger	Director	Sell	5,130	$84.10	$431,433.00	270,414
4/13/2016	Joshua S Boger	Director	Sell	5,130	$84.27	$432,305.10	270,414
4/6/2016	Joshua S Boger	Director	Sell	5,130	$89.56	$459,442.80	270,414
3/30/2016	Joshua S Boger	Director	Sell	5,130	$78.83	$404,397.90	270,414
3/23/2016	Joshua S Boger	Director	Sell	5,130	$81.38	$417,479.40	270,414
3/16/2016	Joshua S Boger	Director	Sell	5,130	$79.65	$408,604.50	270,414
3/2/2016	Joshua S Boger	Director	Sell	5,130	$91.80	$470,934.00	274,425
2/24/2016	Joshua S Boger	Director	Sell	5,130	$85.25	$437,332.50	274,425
2/17/2016	Joshua S. Boger	Director	Sell	5,130	$86.93	$445,950.90	265,284
2/10/2016	Joshua S. Boger	Director	Sell	5,130	$82.57	$423,584.10	265,284
2/3/2016	Ian F. Smith	CFO	Sell	12,084	$90.84	$1,097,710.56	112,999
2/3/2016	Jeffrey M. Leiden	CEO	Sell	9,834	$90.82	$893,123.88	261,885
2/3/2016	Joshua S. Boger	Director	Sell	5,130	$90.81	$465,855.30	265,284
2/3/2016	Paul M. Silva	SVP	Sell	5,062	$90.82	$459,730.84	16,750
2/3/2016	Stuart A. Arbuckle	EVP	Sell	6,042	$90.82	$548,734.44	115,721
2/2/2016	Jeffrey Chodakewitz	CMO	Sell	2,375	$91.38	$217,027.50	112,603
1/27/2016	Joshua S. Boger	Director	Sell	11,200	$93.22	$1,044,064.00	265,284
1/20/2016	Joshua S. Boger	Director	Sell	10,400	$93.69	$974,376.00	265,284
1/13/2016	Joshua S. Boger	Director	Sell	10,400	$98.41	$1,023,464.00	265,284
1/6/2016	Joshua S. Boger	Director	Sell	10,400	$121.96	$1,268,384.00	265,284
1/4/2016	Yuchun Lee	Director	Sell	1,125	$122.21	$137,486.25	1,041
12/30/2015	Joshua S. Boger	Director	Sell	10,400	$127.15	$1,322,360.00	265,284
12/21/2015	Joshua S. Boger	Director	Sell	10,400	$119.26	$1,240,304.00	265,284
12/9/2015	Joshua S. Boger	Director	Sell	10,400	$120.80	$1,256,320.00	265,284
12/4/2015	Stuart A. Arbuckle	EVP	Sell	4,531	$123.98	$561,753.38	104,464
12/2/2015	Joshua S. Boger	Director	Sell	10,400	$130.91	$1,361,464.00	265,284
12/1/2015	David Altshuler	EVP	Sell	5,000	$131.00	$655,000.00	75,000
12/1/2015	Yuchun Lee	Director	Sell	1,125	$129.65	$145,856.25	833
11/23/2015	Joshua S. Boger	Director	Sell	10,400	$132.18	$1,374,672.00	265,284
11/11/2015	Joshua S. Boger	Director	Sell	10,400	$118.59	$1,233,336.00	345,284
11/4/2015	Joshua S. Boger	Director	Sell	10,400	$124.23	$1,291,992.00	345,284
11/2/2015	Yuchun Lee	Director	Sell	1,125	$126.19	$141,963.75	625
10/28/2015	Joshua S. Boger	Director	Sell	10,400	$119.01	$1,237,704.00	345,284
10/21/2015	Joshua S. Boger	Director	Sell	10,400	$108.82	$1,131,728.00	345,284
10/14/2015	Joshua S. Boger	Director	Sell	10,400	$112.62	$1,171,248.00	345,284
10/7/2015	Joshua S. Boger	Director	Sell	10,400	$109.61	$1,139,944.00	345,284
10/2/2015	Elaine Ullian	Director	Sell	20,000	$110.00	$2,200,000.00	5,265
10/1/2015	Stuart A. Arbuckle	EVP	Sell	12,417	$104.71	$1,300,184.07	115,098
10/1/2015	Yuchun Lee	Director	Sell	1,125	$104.64	$117,720.00	416
9/30/2015	Joshua S. Boger	Director	Sell	10,400	$103.14	$1,072,656.00	345,284
9/23/2015	Joshua S. Boger	Director	Sell	10,400	$111.89	$1,163,656.00	345,284
9/16/2015	Joshua S. Boger	Director	Sell	10,400	$133.24	$1,385,696.00	345,284
9/9/2015	Joshua S. Boger	Director	Sell	10,400	$131.41	$1,366,664.00	345,284
9/4/2015	Stuart A. Arbuckle	EVP	Sell	9,063	$125.77	$1,139,853.51	127,515
9/2/2015	Joshua S. Boger	Director	Sell	10,400	$125.85	$1,308,840.00	345,284
9/1/2015	Yuchun Lee	Director	Sell	1,125	$125.40	$141,075.00	208
8/26/2015	Joshua S. Boger	Director	Sell	10,400	$124.71	$1,296,984.00	345,284
8/19/2015	Joshua S. Boger	Director	Sell	10,400	$139.93	$1,455,272.00	345,284
8/12/2015	Joshua S Boger	Director	Sell	10,400	$135.83	$1,412,632.00
7/22/2015	Joshua S Boger	Director	Sell	10,400	$130.92	$1,361,568.00
7/15/2015	Joshua S Boger	Director	Sell	12,200	$133.98	$1,634,556.00
7/13/2015	Paul M Silva	SVP	Sell	1,125	$123.79	$139,263.75
7/8/2015	Joshua S Boger	Director	Sell	11,700	$122.74	$1,436,058.00
7/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$129.36	$296,363.76
7/1/2015	Joshua S Boger	Director	Sell	11,700	$125.60	$1,469,520.00
6/24/2015	Joshua S Boger	Director	Sell	11,700	$130.41	$1,525,797.00
6/17/2015	Joshua S Boger	Director	Sell	11,700	$123.90	$1,449,630.00
6/10/2015	Joshua S Boger	Director	Sell	11,700	$125.02	$1,462,734.00
5/20/2015	Joshua S Boger	Director	Sell	11,700	$126.73	$1,482,741.00
5/6/2015	Joshua S Boger	Director	Sell	11,700	$122.79	$1,436,643.00
5/5/2015	Paul M Silva	SVP	Sell	4,101	$123.68	$507,211.68
4/29/2015	Joshua S Boger	Director	Sell	11,700	$124.59	$1,457,703.00
4/27/2015	Paul M Silva	SVP	Sell	1,125	$129.74	$145,957.50
4/27/2015	Stuart A Arbuckle	EVP	Sell	61,480	$129.36	$7,953,052.80
4/27/2015	Terrence C Kearney	Director	Sell	68,125	$129.11	$8,795,618.75
4/22/2015	Joshua S Boger	Director	Sell	11,700	$132.46	$1,549,782.00
4/15/2015	Joshua S Boger	Director	Sell	11,700	$129.25	$1,512,225.00
4/13/2015	Paul M Silva	SVP	Sell	1,125	$128.60	$144,675.00
4/8/2015	Joshua S Boger	Director	Sell	11,700	$123.26	$1,442,142.00
4/6/2015	Margaret G Mcglynn	Director	Sell	12,500	$118.36	$1,479,500.00
4/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$115.50	$264,610.50
4/1/2015	Joshua S Boger	Director	Sell	11,700	$115.87	$1,355,679.00
3/25/2015	Joshua S Boger	Director	Sell	11,700	$120.76	$1,412,892.00
3/23/2015	Amit Sachdev	EVP	Sell	17,083	$132.28	$2,259,739.24
3/23/2015	Ian F Smith	CFO	Sell	6,042	$125.67	$759,298.14
3/23/2015	Paul M Silva	SVP	Sell	2,250	$125.65	$282,712.50
3/18/2015	Amit Sachdev	EVP	Sell	12,000	$130.00	$1,560,000.00
2/5/2015	Paul M Silva	SVP	Sell	1,688	$109.75	$185,258.00
2/4/2015	Joshua S Boger	Director	Sell	5,700	$108.81	$620,217.00
2/3/2015	Paul M Silva	SVP	Sell	2,063	$108.89	$224,640.07
2/2/2015	Jeffrey Chodakewitz	CMO	Sell	1,188	$109.60	$130,204.80
1/28/2015	Joshua S Boger	Director	Sell	10,688	$122.78	$1,312,272.64
1/26/2015	Paul M Silva	SVP	Sell	1,125	$125.62	$141,322.50
1/21/2015	Joshua S Boger	Director	Sell	10,500	$125.08	$1,313,340.00
1/14/2015	Joshua S Boger	Director	Sell	10,500	$120.16	$1,261,680.00
1/9/2015	Amit Sachdev	EVP	Sell	12,000	$125.00	$1,500,000.00
1/9/2015	Bruce I Sachs	Director	Sell	9,861	$125.04	$1,233,019.44
1/7/2015	Joshua S Boger	Director	Sell	10,500	$119.32	$1,252,860.00
1/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$122.54	$280,739.14
12/22/2014	Joshua S Boger	Director	Sell	10,500	$117.65	$1,235,325.00
12/17/2014	Joshua S Boger	Director	Sell	10,500	$110.66	$1,161,930.00
12/15/2014	Jeffrey M Leiden	CEO	Sell	50,017	$114.97	$5,750,454.49
12/12/2014	Paul M Silva	SVP	Sell	2,813	$120.08	$337,785.04
11/28/2014	Amit Sachdev	EVP	Sell	12,000	$120.00	$1,440,000.00
11/28/2014	Bruce I Sachs	Director	Sell	10,000	$120.03	$1,200,300.00
11/28/2014	Paul M Silva	SVP	Sell	8,164	$119.85	$978,455.40
11/26/2014	Joshua S Boger	Director	Sell	10,500	$114.54	$1,202,670.00
11/6/2014	Bruce I Sachs	Director	Sell	9,900	$115.21	$1,140,579.00
11/5/2014	Bruce I Sachs	Director	Sell	30,100	$112.62	$3,389,862.00
11/3/2014	Joshua S Boger	Director	Sell	127,411	$112.20	$14,295,514.20
10/29/2014	Joshua S Boger	Director	Sell	10,500	$109.44	$1,149,120.00
10/28/2014	Amit Sachdev	EVP	Sell	12,000	$115.00	$1,380,000.00
10/28/2014	David Altshuler	Director	Sell	2,000	$114.75	$229,500.00
10/28/2014	Jeffrey Chodakewitz	CMO	Sell	3,438	$115.00	$395,370.00
10/27/2014	Paul M Silva	SVP	Sell	1,125	$110.03	$123,783.75
10/13/2014	Paul M Silva	SVP	Sell	1,125	$107.89	$121,376.25
10/7/2014	Jeffrey Chodakewitz	CMO	Sell	3,436	$104.26	$358,237.36
10/6/2014	David Altshuler	Director	Sell	1,405	$109.75	$154,198.75
10/1/2014	Elaine Ullian	Director	Sell	5,000	$107.74	$538,700.00
10/1/2014	Stuart A Arbuckle	EVP	Sell	12,417	$107.71	$1,337,435.07
9/30/2014	Amit Sachdev	SVP	Sell	86,000	$112.68	$9,690,480.00
9/30/2014	Ian F Smith	CFO	Sell	108,026	$112.68	$12,172,369.68
9/30/2014	Jeffrey M Leiden	CEO	Sell	200,000	$112.69	$22,538,000.00
9/30/2014	Kenneth L Horton	EVP	Sell	36,000	$112.69	$4,056,840.00
9/29/2014	David Altshuler	Director	Sell	2,500	$114.75	$286,875.00
9/24/2014	Joshua S Boger	Director	Sell	5,200	$109.21	$567,892.00
9/19/2014	David Altshuler	Director	Sell	5,000	$102.25	$511,250.00
9/19/2014	Paul M Silva	SVP	Sell	25,408	$99.85	$2,536,988.80
9/19/2014	Stuart A Arbuckle	EVP	Sell	55,521	$100.00	$5,552,100.00
9/17/2014	Joshua S Boger	Director	Sell	5,200	$93.62	$486,824.00
9/10/2014	Joshua S Boger	Director	Sell	5,200	$94.42	$490,984.00
9/5/2014	David Altshuler	Director	Sell	2,500	$94.75	$236,875.00
9/3/2014	Joshua S Boger	Director	Sell	5,200	$92.79	$482,508.00
8/27/2014	Joshua S Boger	Director	Sell	5,200	$93.31	$485,212.00
8/20/2014	Joshua S Boger	Director	Sell	5,200	$91.51	$475,852.00
8/13/2014	Joshua S Boger	Director	Sell	5,200	$88.00	$457,600.00
8/6/2014	Joshua S Boger	Director	Sell	5,200	$86.54	$450,008.00
7/31/2014	David Altshuler	Director	Sell	5,000	$89.59	$447,950.00
7/31/2014	Paul M Silva	SVP	Sell	2,027	$88.97	$180,342.19
7/30/2014	Joshua S Boger	Director	Sell	5,200	$92.17	$479,284.00
7/15/2014	Wayne Joseph Riley	Director	Sell	4,800	$96.65	$463,920.00
7/1/2014	Elaine Ullian	Director	Sell	5,000	$95.21	$476,050.00
7/1/2014	Kenneth L Horton	EVP	Sell	30,134	$95.22	$2,869,359.48
6/24/2014	Megan E Pace	SVP	Sell	12,734	$98.03	$1,248,314.02
6/24/2014	Wayne Joseph Riley	Director	Sell	15,000	$98.03	$1,470,450.00
6/16/2014	Peter Mueller	EVP	Sell	7,500	$68.31	$512,325.00
6/9/2014	Elaine Ullian	Director	Sell	2,500	$75.00	$187,500.00
5/14/2014	Peter Mueller	EVP	Sell	7,500	$67.45	$505,875.00	143,517
5/2/2014	Megan Pace	SVP	Sell	1,000	$67.62	$67,620.00	23,350
4/15/2014	Peter Mueller	EVP	Sell	7,500	$61.63	$462,225.00	158,750
4/9/2014	Elaine Ullian	Director	Sell	2,500	$70.00	$175,000.00	5,265
3/21/2014	Bruce Sachs	Director	Sell	8,700	$74.59	$648,933.00	21,210
3/17/2014	Peter Mueller	EVP	Sell	7,500	$78.29	$587,175.00	158,750
2/7/2014	Jeffrey Leiden	CEO	Sell	35,944	$80.00	$2,875,520.00	211,481
1/22/2014	Bruce Sachs	Director	Sell	8,300	$84.47	$701,101.00	38,210
1/21/2014	Megan Pace	SVP	Sell	1,250	$85.00	$106,250.00	10,100
1/16/2014	Jeffrey Leiden	CEO	Sell	45,000	$80.00	$3,600,000.00	182,925
1/15/2014	Peter Mueller	EVP	Sell	7,500	$78.67	$590,025.00	141,500
12/23/2013	Bruce Sachs	Director	Sell	8,300	$73.02	$606,066.00	46,510
12/16/2013	Peter Mueller	EVP	Sell	7,500	$64.69	$485,175.00	141,500
12/12/2013	Jeffrey Leiden	CEO	Sell	9,834	$65.48	$643,930.32	182,925
12/12/2013	Kenneth Horton	EVP	Sell	4,532	$65.46	$296,664.72	16,624
12/12/2013	Megan Pace	SVP	Sell	5,083	$65.48	$332,834.84	12,188
12/4/2013	Joshua Boger	Director	Sell	1,400	$67.48	$94,472.00	338,895
11/25/2013	Joshua Boger	Director	Sell	1,400	$66.89	$93,646.00	338,895
11/20/2013	Bruce Sachs	Director	Sell	8,300	$65.28	$541,824.00	54,810
11/19/2013	Joshua Boger	Director	Sell	1,400	$62.31	$87,234.00	338,895
11/5/2013	Joshua Boger	Director	Sell	1,400	$65.64	$91,896.00	338,895
10/29/2013	Joshua S Boger	Director	Sell	1,400	$75.42	$105,588.00
10/29/2013	Thomas Connolly	SVP	Sell	1,688	$75.04	$126,667.52
10/24/2013	Bruce I Sachs	Director	Sell	8,300	$77.06	$639,598.00
10/23/2013	Joshua S Boger	Director	Sell	1,400	$76.77	$107,478.00
10/16/2013	Joshua S Boger	Director	Sell	1,400	$75.41	$105,574.00
10/15/2013	Peter Mueller	EVP	Sell	7,500	$73.25	$549,375.00
10/14/2013	Paul Silva	SVP	Sell	1,593	$71.87	$114,488.91	11,750
10/9/2013	Joshua Boger	Director	Sell	1,400	$72.35	$101,290.00	338,895
9/25/2013	Joshua Boger	Director	Sell	1,400	$74.72	$104,608.00	338,895
9/18/2013	Joshua Boger	Director	Sell	1,400	$77.43	$108,402.00	338,895
9/16/2013	Peter Mueller	EVP	Sell	7,500	$77.22	$579,150.00	144,400
9/11/2013	Joshua Boger	Director	Sell	1,400	$79.61	$111,454.00	338,895
9/4/2013	Joshua Boger	Director	Sell	1,400	$75.45	$105,630.00	338,895
8/29/2013	Bruce Sachs	Director	Sell	8,300	$77.19	$640,677.00	79,710
8/28/2013	Joshua Boger	Director	Sell	1,400	$76.24	$106,736.00	338,895
8/21/2013	Joshua Boger	Director	Sell	1,400	$76.96	$107,744.00	338,895
8/15/2013	Peter Mueller	EVP	Sell	7,500	$77.41	$580,575.00	144,400
8/14/2013	Joshua Boger	Director	Sell	1,400	$77.18	$108,052.00	338,895
8/7/2013	Joshua Boger	Director	Sell	1,400	$77.84	$108,976.00	338,895
8/5/2013	Paul Silva	SVP	Sell	3,001	$78.90	$236,778.90	11,750
7/31/2013	Joshua S Boger	Director	Sell	1,400	$80.89	$113,246.00
7/29/2013	Wayne Joseph Riley	Director	Sell	9,800	$80.09	$784,882.00
7/25/2013	Paul M Silva	SVP	Sell	1,125	$86.49	$97,301.25
7/24/2013	Bruce I Sachs	Director	Sell	8,300	$85.50	$709,650.00
7/19/2013	Amit Sachdev	SVP	Sell	22,250	$88.69	$1,973,352.50
7/18/2013	Joshua S Boger	Director	Sell	1,400	$86.12	$120,568.00
7/16/2013	Paul M Silva	SVP	Sell	2,063	$86.25	$177,933.75
7/15/2013	Christiana Stamoulis	SVP	Sell	1,125	$86.35	$97,143.75
7/15/2013	Peter Mueller	EVP	Sell	7,500	$86.34	$647,550.00
7/12/2013	Megan E Pace	SVP	Sell	10,678	$85.00	$907,630.00
7/11/2013	Joshua S Boger	Director	Sell	1,400	$83.83	$117,362.00
7/8/2013	Kenneth L Horton	EVP	Sell	1,813	$80.72	$146,345.36
7/8/2013	Megan E Pace	SVP	Sell	28,703	$80.89	$2,321,785.67
7/5/2013	Christiana Stamoulis	SVP	Sell	4,687	$81.21	$380,631.27
7/3/2013	Joshua S Boger	Director	Sell	1,400	$80.20	$112,280.00
7/2/2013	Peter Mueller	EVP	Sell	122,300	$79.80	$9,759,540.00
6/26/2013	Joshua S Boger	Director	Sell	1,400	$78.59	$110,026.00
6/21/2013	Bruce I Sachs	Director	Sell	8,300	$75.93	$630,219.00
6/19/2013	Joshua S Boger	Director	Sell	1,400	$79.11	$110,754.00
6/12/2013	Joshua S Boger	Director	Sell	1,400	$81.19	$113,666.00
6/5/2013	Joshua S Boger	Director	Sell	1,400	$77.15	$108,010.00
5/30/2013	Joshua S Boger	Director	Sell	1,400	$82.47	$115,458.00
5/22/2013	Joshua S Boger	Director	Sell	1,400	$79.72	$111,608.00
5/15/2013	Joshua S Boger	Director	Sell	1,400	$79.36	$111,104.00
5/14/2013	Bruce I Sachs	Director	Sell	60,000	$81.15	$4,869,000.00
12/26/2012	Joshua S Boger	Director	Sell	4,000	$41.86	$167,440.00
11/7/2012	Margaret G Mcglynn	Director	Buy	1,000	$45.50	$45,500.00
10/8/2012	Ian F Smith	CFO	Sell	44,787	$60.00	$2,687,220.00
10/3/2012	Joshua S Boger	Director	Sell	4,000	$57.74	$230,960.00
9/5/2012	Joshua S Boger	Director	Sell	4,000	$54.70	$218,800.00

(Data available from 1/1/2013 forward)

Vertex Pharmaceuticals (NASDAQ VRTX) News Headlines

Source:

Date	Headline
	Vertex Pharmaceuticals (VRTX) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 20 at 1:18 PM
	Vertex Pharmaceuticals (VRTX) SVP Paul M. Silva Sells 859 Shares www.americanbankingnews.com - April 19 at 7:36 PM
	Stuart A. Arbuckle Sells 2,125 Shares of Vertex Pharmaceuticals (VRTX) Stock www.americanbankingnews.com - April 18 at 4:10 PM
	Vertex Pharmaceuticals (VRTX) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - April 18 at 9:07 AM
	Vertex Pharmaceuticals (VRTX) to Post Q1 2018 Earnings of $0.34 Per Share, Leerink Swann Forecasts www.americanbankingnews.com - April 18 at 7:40 AM
	Vertex Pharmaceuticals (VRTX) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 2:46 AM
	Vertex to Announce First Quarter 2018 Financial Results on April 26 finance.yahoo.com - April 17 at 5:39 PM
	Vetr Upgrades Vertex Pharmaceuticals (VRTX) to "Strong-Buy" www.americanbankingnews.com - April 17 at 4:47 PM
	Vertex Pharmaceuticals (VRTX) Stock Rating Upgraded by Barclays www.americanbankingnews.com - April 17 at 12:04 AM
	Vertex Pharmaceuticals (VRTX) Upgraded to Outperform at Cowen www.americanbankingnews.com - April 17 at 12:04 AM
	Vertex Pharmaceuticals (VRTX) Given New $194.00 Price Target at Piper Jaffray www.americanbankingnews.com - April 17 at 12:04 AM
	Vertex Pharmaceuticals (VRTX) Lowered to Buy at Vetr www.americanbankingnews.com - April 16 at 11:29 PM
	Vertex Pharmaceuticals (VRTX) Given a $195.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - April 15 at 4:33 PM
	Vertex Pharmaceuticals (VRTX) Given a $184.00 Price Target at JPMorgan Chase www.americanbankingnews.com - April 15 at 3:59 PM
	Vertex Pharmaceuticals (VRTX) Stock Rating Upgraded by Vetr www.americanbankingnews.com - April 15 at 9:31 AM
	Vertex Pharmaceuticals (VRTX) PT Raised to $175.00 www.americanbankingnews.com - April 14 at 3:07 PM
	Vertex Pharmaceuticals (VRTX) Lifted to "Hold" at BidaskClub www.americanbankingnews.com - April 13 at 9:39 AM
	$608.83 Million in Sales Expected for Vertex Pharmaceuticals (VRTX) This Quarter www.americanbankingnews.com - April 13 at 4:31 AM
	Vertex Pharmaceuticals' (VRTX) "Buy" Rating Reiterated at Jefferies Group www.americanbankingnews.com - April 9 at 11:59 PM
	Vertex Pharmaceuticals (VRTX) Lowered to "Buy" at Vetr www.americanbankingnews.com - April 9 at 3:30 PM
	Insider Selling: Vertex Pharmaceuticals (VRTX) SVP Sells 3,438 Shares of Stock www.americanbankingnews.com - April 4 at 10:56 PM
	Vertex Pharmaceuticals (VRTX) Stock Rating Reaffirmed by Piper Jaffray www.americanbankingnews.com - April 4 at 8:34 PM
	Q-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery Collaboration www.businesswire.com - April 4 at 8:42 AM
	Concert Therapeutics Will See A Second Wind In Coming Months seekingalpha.com - April 3 at 5:15 PM
	Zacks Investment Research Upgrades Vertex Pharmaceuticals (VRTX) to Strong-Buy www.americanbankingnews.com - March 30 at 12:48 PM
	Vertex Pharmaceuticals (VRTX) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - March 30 at 11:06 AM
	Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer finance.yahoo.com - March 29 at 5:12 PM
	Why Regeneron Pharmaceuticals’ Stock Price Fell finance.yahoo.com - March 29 at 5:12 PM
	Is Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) PE Ratio A Signal To Sell For Investors? finance.yahoo.com - March 28 at 8:50 AM
	$608.99 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter www.americanbankingnews.com - March 27 at 7:08 AM
	Vertex Pharmaceuticals (VRTX) Given New $200.00 Price Target at Barclays www.americanbankingnews.com - March 25 at 10:57 PM
	Vertex Pharmaceuticals (VRTX) Receives Buy Rating from Jefferies Group www.americanbankingnews.com - March 25 at 10:22 PM
	Vertex Pharmaceuticals (VRTX) PT Raised to $200.00 www.americanbankingnews.com - March 25 at 10:22 PM
	Vertex Pharmaceuticals (VRTX) Raised to "B-" at TheStreet www.americanbankingnews.com - March 24 at 11:25 AM
	Vertex Pharmaceuticals Incorporated (VRTX) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - March 24 at 8:28 AM
	Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud' - Benzinga www.benzinga.com - March 21 at 9:24 AM
	Vertex Pharmaceuticals (VRTX) Raised to Hold at BidaskClub www.americanbankingnews.com - March 18 at 4:24 PM
	NYSE trader: Out of control deficit spending will come to bite us someday finance.yahoo.com - March 16 at 6:10 PM
	Trying the Long Side of Vertex's Stock Again finance.yahoo.com - March 16 at 6:10 PM
	7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock www.msn.com - March 15 at 5:47 PM
	No. 1-Ranked Drug-Trial Stock And IBD 50 Member Examines Buy Zone finance.yahoo.com - March 15 at 8:36 AM
	Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $2,406,250.00 in Stock www.americanbankingnews.com - March 12 at 7:21 PM
	Vertex to Present at the Cowen Healthcare Conference on March 13 finance.yahoo.com - March 12 at 6:18 PM
	Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $608.99 Million www.americanbankingnews.com - March 10 at 10:22 AM
	Analysts Anticipate Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.52 Per Share www.americanbankingnews.com - March 8 at 1:08 AM
	Renaissance Technologies LLC Has $426.79 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX) www.americanbankingnews.com - March 6 at 2:52 PM
	MYDA Advisors LLC Buys New Stake in Vertex Pharmaceuticals Incorporated (VRTX) www.americanbankingnews.com - March 6 at 2:46 PM
	Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) Director Sells 10,000 Shares of Stock www.americanbankingnews.com - March 5 at 9:11 PM
	Green Valley Investors LLC Trims Holdings in Vertex Pharmaceuticals Incorporated (VRTX) www.americanbankingnews.com - March 5 at 4:07 PM
	Sectoral Asset Management Inc Boosts Stake in Vertex Pharmaceuticals Incorporated (VRTX) www.americanbankingnews.com - March 5 at 3:34 PM

Vertex Pharmaceuticals (NASDAQ:VRTX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Vertex Pharmaceuticals (NASDAQ:VRTX) Income Statement, Balance Sheet and Cash Flow Statement

Vertex Pharmaceuticals (NASDAQ VRTX) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff